A Replicating Single-Cycle Adenovirus Vaccine Against Ebola Virus

Autor: Stephanie S. Anguiano-Zarate, William E. Matchett, Pramod N. Nehete, Jagannadha K. Sastry, Michael A. Barry, Andrea Marzi
Rok vydání: 2018
Předmět:
0301 basic medicine
Aging
Dose-Response Relationship
Immunologic
Enzyme-Linked Immunosorbent Assay
Antibodies
Viral
Virus Replication
medicine.disease_cause
Adenoviridae
Mice
Editorial Commentaries
03 medical and health sciences
0302 clinical medicine
Cricetinae
Chlorocebus aethiops
medicine
Animals
Humans
Immunology and Allergy
030212 general & internal medicine
Vector (molecular biology)
Ebola Vaccines
Adenovirus infection
Vero Cells
Immunization Schedule
Glycoproteins
Vaccines
Synthetic
Ebola virus
Mesocricetus
biology
Hemorrhagic Fever
Ebola
Ebolavirus
biology.organism_classification
medicine.disease
Macaca mulatta
Virology
Adenovirus vaccine
HEK293 Cells
030104 developmental biology
Infectious Diseases
Viral replication
A549 Cells
Vesicular stomatitis virus
Vero cell
Female
medicine.drug
Zdroj: The Journal of Infectious Diseases. 218:1883-1889
ISSN: 1537-6613
0022-1899
Popis: Recent West African Ebola virus (EBOV) epidemics have led to testing different anti-EBOV vaccines, including a replication-defective adenovirus (RD-Ad) vector (ChAd3-EBOV) and an infectious, replication-competent recombinant vesicular stomatitis virus expressing the EBOV glycoprotein (rVSV-EBOV; also known as rVSV-ZEBOV). While RD-Ads elicit protection, when scaled up to human trials, the level of protection may be much lower than that of vaccines containing viruses that can replicate. Although a replication-competent Ad (RC-Ad) vaccine might generate a level of protection approximating that of rVSV, this infectious vector would also risk causing adenovirus disease. We recently described a "single-cycle" adenovirus (SC-Ad) vector that amplifies antigen genes like RC-Ad, but that avoids the risk of adenovirus infection. Here we have tested an SC-Ad6 vector expressing the glycoprotein (GP) from a 2014 EBOV strain in mice, hamsters, and rhesus macaques. We show that SC-Ad6-EBOV GP induces a high level of serum antibodies in all species and mediates significant protection against pseudo-challenge with rVSV-EBOV expressing luciferase in mice and hamsters. These data suggest that SC-Ad6-EBOV GP may be useful during future EBOV outbreaks.
Databáze: OpenAIRE
Externí odkaz: